Efficacy and safety of alisporivir for the treatment of hepatitis C infection
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy and safety of alisporivir for the treatment of hepatitis C infection
Authors
Keywords
-
Journal
EXPERT OPINION ON PHARMACOTHERAPY
Volume -, Issue -, Pages 1-6
Publisher
Informa UK Limited
Online
2018-12-22
DOI
10.1080/14656566.2018.1560424
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection
- (2018) Ulrich Spengler PHARMACOLOGY & THERAPEUTICS
- EASL Recommendations on Treatment of Hepatitis C 2016
- (2017) JOURNAL OF HEPATOLOGY
- Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older
- (2017) Anca Trifan et al. MEDICINE
- Hepatitis C Virus-Genotype 3: Update on Current and Emergent Therapeutic Interventions
- (2017) Steven W. Johnson et al. Current Infectious Disease Reports
- Hepatitis C virus resistance to the new direct-acting antivirals
- (2016) Isabella Esposito et al. Expert Opinion on Drug Metabolism & Toxicology
- Prevention and management of treatment failure to new oral hepatitis C drugs
- (2016) Laura Benítez-Gutiérrez et al. EXPERT OPINION ON PHARMACOTHERAPY
- Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+)
- (2016) Vincent Leroy et al. HEPATOLOGY
- The importance of resistance to direct antiviral drugs in HCV infection in clinical practice
- (2016) Christoph Sarrazin JOURNAL OF HEPATOLOGY
- Update on Current Evidence for Hepatitis C Therapeutic Options in HCV Mono-infected Patients
- (2016) Mark W. Hull et al. Current Infectious Disease Reports
- Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II)
- (2015) S. Zeuzem et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Alisporivir plus ribavirin, interferon free or in combination with pegylated interferon, for hepatitis C virus genotype 2 or 3 infection
- (2015) Jean-Michel Pawlotsky et al. HEPATOLOGY
- All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study
- (2015) David R. Nelson et al. HEPATOLOGY
- Therapy for hepatitis C genotype 3: moving forward
- (2015) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Treatment of hepatitis C in difficult-to-treat patients
- (2015) Peter Ferenci Nature Reviews Gastroenterology & Hepatology
- Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection
- (2015) Graham R. Foster et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Novel Cyclophilin Inhibitor CPI-431-32 Concurrently Blocks HCV and HIV-1 Infections via a Similar Mechanism of Action
- (2015) Philippe A. Gallay et al. PLoS One
- The Combination of Alisporivir plus an NS5A Inhibitor Provides Additive to Synergistic Anti-Hepatitis C Virus Activity without Detectable Cross-Resistance
- (2014) Udayan Chatterji et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
- (2014) Ivan Gentile et al. Expert Review of Anti-Infective Therapy
- Cyclophilin Inhibitors Reduce Phosphorylation of RNA-Dependent Protein Kinase to Restore Expression of IFN-Stimulated Genes in HCV-Infected Cells
- (2014) Takuji Daito et al. GASTROENTEROLOGY
- Cyclophilin inhibition as potential therapy for liver diseases
- (2014) Nikolai V. Naoumov JOURNAL OF HEPATOLOGY
- Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial
- (2014) M. Buti et al. JOURNAL OF VIRAL HEPATITIS
- Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3
- (2014) Stefan Zeuzem et al. NEW ENGLAND JOURNAL OF MEDICINE
- Hepatitis C NS5A protein: two drug targets within the same protein with different mechanisms of resistance
- (2014) Precious J Lim et al. Current Opinion in Virology
- Novel Therapeutic Approaches for Hepatitis C
- (2013) J S Au et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Emerging treatments for hepatitis C
- (2013) Robert Flisiak et al. EXPERT OPINION ON EMERGING DRUGS
- 821 INTERFERON (IFN)-FREE ALISPORIVIR (ALV) HAS A BETTER OVERALL SAFETY PROFILE COMPARED TO IFN-CONTAINING TREATMENT: A POOLED ANALYSIS OF THE ALV DEVELOPMENT PROGRAM
- (2013) L. Griffel et al. JOURNAL OF HEPATOLOGY
- Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890
- (2013) Christophe Hézode et al. JOURNAL OF HEPATOLOGY
- Profile of alisporivir and its potential in the treatment of hepatitis C
- (2013) Philippe Gallay et al. Drug Design Development and Therapy
- Update on alisporivir in treatment of viral hepatitis C
- (2012) Robert Flisiak et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- 466 PREDICTORS OF SUSTAINED VIROLOGIC RESPONSE AMONG TREATMENT-NAIVE PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 WHEN TREATED WITH BOCEPREVIR (BOC) PLUS PEGINTERFERON ALFA-2B/RIBAVIRIN (PR)
- (2011) K.R. Reddy et al. JOURNAL OF HEPATOLOGY
- The invaders and the barrier
- (2011) Jean-Michel Pawlotsky JOURNAL OF HEPATOLOGY
- Structural Basis for the Non-Immunosuppressive Character of the Cyclosporin A Analogue Debio 025
- (2010) Isabelle Landrieu et al. BIOCHEMISTRY
- Cyclosporine Inhibits a Direct Interaction between Cyclophilins and Hepatitis C NS5A
- (2010) Fiona Fernandes et al. PLoS One
- DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
- (2010) Lotte Coelmont et al. PLoS One
- An evaluation of the cyclophilin inhibitor Debio 025 and its potential as a treatment for chronic hepatitis C
- (2009) Raf Crabbé et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- The cyclophilin inhibitor Debio 025 combined with PEG IFNα2a significantly reduces viral load in treatment-naïve hepatitis C patients
- (2009) Robert Flisiak et al. HEPATOLOGY
- Hepatitis C Virus NS5A Protein Is a Substrate for the Peptidyl-prolylcis/transIsomerase Activity of Cyclophilins A and B
- (2009) Xavier Hanoulle et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- The Isomerase Active Site of Cyclophilin A Is Critical for Hepatitis C Virus Replication
- (2009) Udayan Chatterji et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- 946 PK-PD MODELING OF VIRAL KINETICS DURING TREATMENT WITH DEBIO-025 PLUS PEGYLATED INTERFERON ALPHA-2A IN TREATMENT-NAIVE HCV PATIENTS
- (2009) E. Herrmann et al. JOURNAL OF HEPATOLOGY
- 95 EFFICACY AND SAFETY OF THE CYCLOPHILIN INHIBITOR DEBIO 025 IN COMBINATION WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN IN PREVIOUSLY NULL-RESPONDER GENOTYPE 1 HCV PATIENTS
- (2009) D.R. Nelson et al. JOURNAL OF HEPATOLOGY
- Critical Role of Cyclophilin A and Its Prolyl-Peptidyl Isomerase Activity in the Structure and Function of the Hepatitis C Virus Replication Complex
- (2009) Z. Liu et al. JOURNAL OF VIROLOGY
- The cyclophilin inhibitor Debio-025 shows potent anti-hepatitis C effect in patients coinfected with hepatitis C and human immunodeficiency virus
- (2008) Robert Flisiak et al. HEPATOLOGY
- Current and future management of chronic hepatitis C infection
- (2008) T J S Cross et al. POSTGRADUATE MEDICAL JOURNAL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now